![](https://ml.globenewswire.com/media/21920774-d9c9-4c88-9a02-3a33a53714e8/medium/filspari-sparsentan.png)
Travere Therapeutics Announces Full FDA Approval of FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment ...
FDA approves expanded indication making FILSPARI available to patients with IgA nephropathy (IgAN) at risk of progression; updated label includes data showing long-term durable benefit on proteinuria and kidney function preservation that accrued over two …